News Releases

- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation of the tumor microenvironment and immune activation - - Translational analyses

-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung

WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation   ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences. Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick,

WESTLAKE VILLAGE, Calif. , Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation   ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board; Matt Pulisic , Chief Financial Officer; and Dr.

WESTLAKE VILLAGE, Calif. , Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per

WESTLAKE VILLAGE, Calif. , Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock.

-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial

WESTLAKE VILLAGE, Calif. , Jan. 02, 2026 (GLOBE NEWSWIRE) --   Genelux Corporation   ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten , M.D., as Chief Medical Officer, effective January 2, 2026 . Dr.

WESTLAKE VILLAGE, Calif. , Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation   ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board and Matt Pulisic , Chief Financial Officer, will participate in a